REFERENCES
1. Wolfe AD. Pediatric Vascular Anomalies: Opportunities in Primary Care. In: Kamat DM, Frei-Jones M, eds. Benign Hematologic Disorders in Children: A Clinical Guide. Cham: Springer International Publishing; 2021:453-486.
2. Anomalies ISftSoV. ISSVA Classification of Vascular Anomalies. 2018; https://www.issva.org/classification. Accessed March 2, 2021.
3. Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet Journal of Rare Diseases.2021;16(1):306.
4. Trenor CC, Adams DM, eds. Vascular Anomalies: A Guide for the Hematologist/Oncologist. 1 ed. Switzerland: Springer International Publishing; 2020.
5. Kerr AM, Haas SM. Parental uncertainty in illness: managing uncertainty surrounding an ”orphan” illness. Journal of pediatric nursing. 2014;29(5):393-400.
6. Kerr AM, Harrington NG, Scott AM. Communication and the Appraisal of Uncertainty: Exploring Parents’ Communication with Credible Authorities in the Context of Chronic Childhood Illness. Health communication. 2017;34(2):201-211.
7. Kerr AM, Harrington NG, Scott AM. Uncertainty Management and Decision Making: Parents’ Experiences During their First Visit to a Multidisciplinary Clinic for their Child’s Vascular Anomaly.Journal of pediatric nursing. 2020;52:18-24.
8. Kerr AM, Thompson CM, Rubinsky V. Memorable Messages Parents of Children with Vascular Birthmarks Receive from Others: Implications for Stigma and Identity. Health communication. 2020;35(6):685-695.
9. Hammill AM, M. W, A. G, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatric Blood and Cancer. 2011;57(6):1018-1024.
10. Adams DM, Trenor CC, 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.Pediatrics. 2016;137(2):e20153257.
11. Ji Y, Chen S, Yang K, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021.
12. Harbers VEM, Rongen G, van der Vleuten CJM, et al. Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus. Adv Ther. 2021.
13. Maruani A, Tavernier E, Boccara O, et al. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatol. 2021.
14. Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.Pediatr Blood Cancer. 2022:e29603.
15. Ricci KW, Iacobas I. How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr Blood Cancer. 2021:e28985.
16. Queisser A, Seront E, Boon LM, Vikkula M. Genetic Basis and Therapies for Vascular Anomalies. Circ Res. 2021;129(1):155-173.
17. O’Shea AE, Valdera FA, Ensley D, et al. Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention.Clin Immunol. 2022;245:109095.
18. Rossler J, Eulalia B, Victoria D, et al. Severe adverse events during sirolimus ”off-label” therapy for vascular anomalies.Pediatric blood & cancer. 2021;68(8):e28936.
19. Adams DM, C. TC, M. HA, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics.2016;137(2).
20. Maruani A, E. T, O. B, et al. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatology. 2021;157(11):1289-1298.
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLOS Medicine. 2009;6(7):e1000100.
22. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-243.
23. Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020;18(10):2127-2133.
24. Ji Y, S. C, J. Z, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022;139(11):1619-1630.
25. Russell TB, K. RE, S. DC, B. GL, W. MT. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma.Pediatrics. 2018;141:S421-S424.
26. Mäkinen T, Boon LM, Vikkula M, Alitalo K. Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies. Circ Res.2021;129(1):136-154.
27. Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program.2020;2020(1):319-327.
28. Malpica L, van Duin D, Moll S. Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders.Am J Hematol. 2019;94(12):1396-1412.
29. Wang Z, W. Y, H. S, et al. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. Journal of Dermatology. 2019;46(11):956-961.
30. Wang Y, L. K, B. S, J. C, W. S. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.The Journal of craniofacial surgery. 2020;31(4):1074-1077.
31. Ying H, C. Q, X. Y, X. L. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas.Pediatrics. 2018;141:S425-S429.
32. Sandbank S, V. M-P, A. F, A. B, S. G. Oral and topical sirolimus for vascular anomalies: A multicentre study and review. Acta Dermato-Venereologica. 2019;99(11):990-996.